Premium Nahrungsergänzungsmittel | artgerecht

Factor 5 Leiden Mutation: Causes, Symptoms & Treatment

The Factor 5 Leiden mutation is a genetic change that significantly increases the risk of blood clots. It is the most common inherited cause of clotting disorders in people of European descent.

Regular tips about health Regular tips about health

Things worth knowing about "Factor 5 Leiden Mutation"

The Factor 5 Leiden mutation is a genetic change that significantly increases the risk of blood clots. It is the most common inherited cause of clotting disorders in people of European descent.

What Is the Factor 5 Leiden Mutation?

The Factor 5 Leiden mutation (also written as Factor V Leiden mutation) is a genetic variant in the gene encoding clotting factor V. This variant prevents factor V from being properly inactivated, causing the blood to remain in an overactive clotting state. As a result, affected individuals have a significantly increased risk of developing blood clots (thrombosis). It is the most common inherited thrombophilia in European populations, affecting approximately 3–8% of individuals of European descent.

Causes and Inheritance

The mutation is caused by a single nucleotide substitution in the F5 gene on chromosome 1 (guanine replaced by adenine, G1691A). This leads to an amino acid change in the factor V protein (arginine replaced by glutamine at position 506, R506Q), making the mutated factor V resistant to inactivation by the natural anticoagulant activated protein C (APC).

The mutation follows an autosomal dominant inheritance pattern:

Heterozygous carriers: One mutated copy – the risk of thrombosis is 3–8 times higher than average.
Homozygous carriers: Two mutated copies – the risk of thrombosis is 50–80 times higher than average.

Symptoms and Clinical Presentation

The Factor 5 Leiden mutation itself does not cause direct symptoms. However, it significantly increases the risk of the following conditions:

Deep vein thrombosis (DVT): Blood clots forming in the deep veins, most often in the legs
Pulmonary embolism: A clot traveling to and blocking an artery in the lungs
Pregnancy complications: Recurrent miscarriage, preeclampsia, placental insufficiency
Stroke or heart attack (less common, usually in combination with additional risk factors)

Many carriers of the mutation never experience a thrombotic event, especially in the absence of additional risk factors.

Risk Factors

The thrombosis risk increases substantially when the Factor 5 Leiden mutation is combined with other risk factors such as:

Use of estrogen-containing contraceptives (combined oral contraceptive pill)
Pregnancy and the postpartum period
Prolonged immobility (e.g., bed rest, long-haul flights)
Surgery or injury
Additional clotting disorders (e.g., prothrombin mutation, antiphospholipid syndrome)
Obesity, smoking, or advanced age

Diagnosis

Diagnosis is established through laboratory testing on a blood sample, using two main approaches:

APC resistance test (functional): Measures whether factor V responds normally to activated protein C. An abnormal result suggests the presence of the mutation.
Genetic testing (DNA analysis): Confirms the presence of the mutation and determines whether the individual is a heterozygous or homozygous carrier.

Testing is typically recommended in individuals with:

Unexplained or recurrent thrombosis, especially at a young age
A family history of blood clotting disorders
Thrombosis at unusual sites (e.g., mesenteric or cerebral veins)
Recurrent pregnancy loss

Treatment and Management

Carriers of the Factor 5 Leiden mutation do not automatically require treatment. Management is individualized based on the overall thrombotic risk assessment.

Preventive Measures in High-Risk Situations

Heparin injections during high-risk periods (surgery, pregnancy, prolonged immobility)
Wearing compression stockings to improve venous blood flow
Avoiding estrogen-containing contraceptives when the mutation is known

Treatment After a Thrombotic Event

Anticoagulation therapy using direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban, or vitamin K antagonists (e.g., warfarin)
Duration of anticoagulation depends on individual risk (ranging from 3 months to lifelong therapy)

Pregnancy

Pregnant carriers are often treated with low-molecular-weight heparin, as DOACs are contraindicated during pregnancy. Treatment decisions are made on an individual basis in close consultation with a physician.

References

Rosendaal FR - Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–1173.
Dahlbäck B - Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112(1):19–27.
American Society of Hematology - Factor V Leiden Thrombophilia. ASH Clinical Practice Guidelines, 2023. Available at: www.hematology.org

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.